Axcella Health Inc

Axcella Health — Technical Presentation (August 2020)

16 slides from Axcella Health's technical presentation, Aug 5, 2020

  1. Slide 1: AXA1665-002 Top-Line Data

    NASDAQ: AXLA AXA1665-002 Top-Line Data August 5, 2020 © 2020 Axcella Health Inc. All rights reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the characteristics, competitive position and development potential of the comp

  3. Slide 3: About Axcella's Development Model and Clinical Approach

    About Axcella’s Development Model and Clinical Approach EMMs have a fundamental role in biology and function. Using the Axcella Knowledge Base, Axcella designs and develops novel EMM compositions to engage identified biologies and pathways. Axcella then selects whether to evaluate a product candidat

  4. Slide 4: Axcella's Focus: Endogenous Metabolic Modulators (EMMs)

    Axcella’s Focus: Endogenous Metabolic Modulators (EMMs) EMMs Act as Signaling Agents and Master Regulators in Human Biology • EMMs, including amino acids, are well Central Circulatory Nervous established agents used to support health System System • Single EMMs and simple EMM combinations have been

  5. Slide 5: Overt Hepatic Encephalopathy

    Overt Hepatic Encephalopathy A complex disease with unmet need that would benefit from a multifactorial intervention Key Processes Involved in HE Ammonia Handling Unmet Needs: • Limited use of existing treatments: rifaximin and lactulose due in part to tolerability/compliance • Existing treatments d

  6. Slide 6: AXA1665 – Hypothesized Mechanism

    AXA1665 – Hypothesized Mechanism Designed to target multiple metabolic pathways implicated in pathogenesis of HE and muscle wasting in cirrhosis 1665 Rebalance Ile Val Amino Acids His Lys Leu Muscle Leu Ile Val mTORC1 mass Asp Thr Orn Tyr His Protein Glu Synthesis NH3 Phe + Lys Improve Enhance Muscl

  7. Slide 7: AXA1665-001: Initial Proof of Biological Activity in Child A & B Subjects

    AXA1665-001: Initial Proof of Biological Activity in Child A & B Subjects Dose-dependent changes seen in multiple measures in short-term, highly controlled study AXA-001 Clinical Amino Acid Change in Fischer Ratio2 Study Design Imbalance AXA 44.1 g/d (n=10) → Control (n=9) Control (n=7) → AXA 14.7 g

  8. Slide 8: AXA1665-002: A 12-Week Placebo Controlled Study

    AXA1665-002: A 12-Week Placebo Controlled Study in Subjects with Mild (Child A) and Moderate (Child B) Hepatic Insufficiency NCT04147936 12 WEEKS 4 WEEKS D8: W6: W12: W16: AXA1665-002 STUDY DESIGN2 MRI, MRI, MRI, BMx BMx BMx BMx 12-week (with a four-week follow-up), W2 W4 W9 randomized placebo-contr

  9. Slide 9: Demographics Suggest Population with Mostly Mild Hepatic Insufficiency

    Demographics Suggest Population with Mostly Mild Hepatic Insufficiency (Child A), Without Overt Sarcopenia, but with MHE Placebo AXA1665 29.3 g AXA1665 59.3 g Baseline Demographic/Metric (n=11) (n=22) (n=27) Age, years 58.0 (14.4) 58.5 (11.6) 59.0 (9.3) Sex Male, n (%) 6 (54.5) 8 (36.4) 9 (33.3) Fem

  10. Slide 10: Dose Dependent Improvements in Amino Acid Metabolism

    Dose Dependent Improvements in Amino Acid Metabolism Changes in Fischer Ratio from baseline over and at week 12 Amino Acid Change in Fischer Ratio Over Time1 Absolute Change in Fischer Ratio at Week 12 Metabolism 75 3 * 2 50 * 1 1.3 25 0.4 0 mean(SE) mean (SE), (SE), mean % Absolutechange, Percent P

  11. Slide 11: Fasted Plasma Ammonia Levels Stable Despite Added Nitrogen

    Fasted Plasma Ammonia Levels Stable Despite Added Nitrogen in AXA1665 Arms; Greater Reductions Observed in MHE Subgroup Changes from baseline at week 12 Ammonia Handling Subgroup with Overall Safety Cohort Baseline MHE Absolute Change in Ammonia Percent Change in Ammonia Percent Change in Ammonia 15

  12. Slide 12: Measures of Muscle Structure and Function Remained Stable

    In This Non-Sarcopenic Population, Measures of Muscle Structure and Function Remained Stable Across Groups Changes from baseline at week 12 Muscle Metabolism 10 Total Thigh Muscle Volume 10 L3 Skeletal Muscle Index 0.4 2.0 0 0 -2.9 -0.4 mean(SE), % mean (SE), mean(SE), % -0.8 0.0 Percent Percent cha

  13. Slide 13: Dose Dependent Improvement Across Three Measures of Cognitive Function

    Dose Dependent Improvement Consistently Observed Across All Three Measures of Cognitive Function Changes from baseline at week 12 Psychometric Hepatic Encephalopathy Score (PHES) 1 Cognitive Function 60 ≥+2 change in PHES 2 * 1 0.0 1.1 40 0 -1.2 mean(SE) 56.5 -1 Subjects, % 20 Absolutechange, 33.3 -

  14. Slide 14: AXA1665 was Well Tolerated with Low Adverse Event Rates

    AXA1665 was Well Tolerated with Low Adverse Event Rates Subjects with product-emergent adverse events Placebo AXA1665 Low AXA1665 High (PEAEs), n (%)1 (n=11) (n=22) (n=27) All PEAEs 4 (36.4) 8 (36.4) 10 (37.0) All PEAEs reported in ≥10% for any arm: All Gastrointestinal Events 1 (9.1) 2 (9.1) 4 (14.

  15. Slide 15: Summary

    Summary • Further evidence of our ability to design multi-targeted EMM compositions that impact multiple biologies and have been safe and well tolerated to date • Positive, dose dependent trends across measures of neurocognition; statistical significance in PHES • Dose dependent and statistically si

  16. Slide 16: Our thanks to the subjects and investigators who participated in AXA1665-002

    Our thanks to the subjects and investigators who participated in AXA1665-002 Participating Sites: Catalina Research Institute, LLC Atlanta Center for Medical Research Montclair, CA Atlanta, GA Orange County Research Center Delta Research Partners Tustin, CA Bastrop, LA Panax Clinical Research Texas

Axcella Health — Technical Presentation (August 2020) on 6ix